The rise of Viagra initially fueled a surge for pharma, nevertheless recent developments present a murky outlook for shareholders. Lower-cost versions are reducing revenue, and persistent litigation add further https://blakerrvm679175.blogadvize.com/49692141/the-blue-pill-and-the-pharmaceutical-industry-a-volatile-play